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A bs tr ac t
Background
Current guidelines for patients with moderate- or high-risk acute coronary syndromes 
recommend an early invasive approach with concomitant antithrombotic therapy, in-
cluding aspirin, clopidogrel, unfractionated or low-molecular-weight heparin, and gly-
coprotein IIb/IIIa inhibitors. We evaluated the role of thrombin-specific anticoagu-
lation with bivalirudin in such patients.
Methods
We assigned 13,819 patients with acute coronary syndromes to one of three antithrom-
botic regimens: unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa in-
hibitor, bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin alone. The pri-
mary end points were a composite ischemia end point (death, myocardial infarction, 
or unplanned revascularization for ischemia), major bleeding, and the net clinical out-
come, defined as the combination of composite ischemia or major bleeding.
Results
Bivalirudin plus a glycoprotein IIb/IIIa inhibitor, as compared with heparin plus a gly-
coprotein IIb/IIIa inhibitor, was associated with noninferior 30-day rates of the com-
posite ischemia end point (7.7% and 7.3%, respectively), major bleeding (5.3% and 
5.7%), and the net clinical outcome end point (11.8% and 11.7%). Bivalirudin alone, as 
compared with heparin plus a glycoprotein IIb/IIIa inhibitor, was associated with a 
noninferior rate of the composite ischemia end point (7.8% and 7.3%, respectively; 
P = 0.32; relative risk, 1.08; 95% confidence interval [CI], 0.93 to 1.24) and signifi-
cantly reduced rates of major bleeding (3.0% vs. 5.7%; P<0.001; relative risk, 0.53; 
95% CI, 0.43 to 0.65) and the net clinical outcome end point (10.1% vs. 11.7%; P = 0.02; 
relative risk, 0.86; 95% CI, 0.77 to 0.97).
Conclusions
In patients with moderate- or high-risk acute coronary syndromes who were under-
going invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associ-
ated with rates of ischemia and bleeding that were similar to those with heparin. Bivali-
rudin alone was associated with similar rates of ischemia and significantly lower rates 
of bleeding. (ClinicalTrials.gov number, NCT00093158.)
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More than 1.4 million persons are admitted to hospitals in the United States every year with acute coronary syndromes 
(e.g., unstable angina or myocardial infarction 
without ST-segment elevation).1 An early invasive 
strategy for patients with moderate- or high-risk 
acute coronary syndromes, consisting of angiog-
raphy followed by percutaneous coronary inter-
vention (PCI), coronary-artery bypass grafting 
(CABG), or medical management, results in high-
er rates of event-free survival than does conserva-
tive care2 and is recommended by the American 
Heart Association, the American College of Cardi-
ology, and the European Society of Cardiology.3-5 
Aspirin, clopidogrel, a platelet glycoprotein IIb/
IIIa inhibitor, and an antithrombotic agent (either 
unfractionated or low-molecular-weight hepa-
rin) are also recommended for patients for whom 
an invasive strategy is chosen.3-5 Nonetheless, the 
rates of death and myocardial infarction remain 
considerable, and this intensive adjunctive phar-
macologic regimen results in frequent hemorrhag-
ic complications that have been independently 
associated with early and late mortality rates.6-8
Bivalirudin (Angiomax, the Medicines Com-
pany) is a direct-acting synthetic antithrombotic 
agent that has been approved as an alternative to 
unfractionated heparin for patients with acute 
coronary syndromes who are undergoing PCI. In 
the Randomized Evaluation in PCI Linking Angio-
max to Reduced Clinical Events 2 (REPLACE-2) 
trial, bivalirudin monotherapy, as compared with 
unfractionated heparin plus glycoprotein IIb/IIIa 
inhibitors, resulted in a significant reduction in 
rates of major and minor bleeding (as defined in 
the trial), with similar rates of ischemic events and 
death among patients with stable or unstable an-
gina who were undergoing PCI.9,10 We examined 
the usefulness of bivalirudin as part of an early 
invasive strategy with optimal antiplatelet therapy 
in patients with acute coronary syndromes.
Me thods
Study design
The Acute Catheterization and Urgent Intervention 
Triage Strategy (ACUITY) trial was a prospective, 
open-label, randomized, multicenter trial in which 
we compared heparin plus a glycoprotein IIb/IIIa 
inhibitor, bivalirudin plus a glycoprotein IIb/IIIa in-
hibitor, and bivalirudin alone in patients with mod-
erate- or high-risk acute coronary syndromes who 
were undergoing an early invasive strategy. The 
study protocol has been described previously in de-
tail.11 The trial was sponsored by the Medicines 
Company and Nycomed.
The study was designed by Drs. Stone, Ber-
trand, Lincoff, Moses, Ohman, White, Pocock, and 
Ware in collaboration with the sponsors. The ex-
ecution of the study was supervised by the spon-
sors in collaboration with the executive and steer-
ing committees (see the Supplementary Appendix, 
available with the full text of this article at www.
nejm.org). Dr. Stone had full access to the entire 
study database and prepared the manuscript. Data 
analysis was performed by the study sponsors but 
was independently confirmed by the Cardiovascu-
lar Research Foundation, an affiliate of Columbia 
University Medical Center. Dr. Stone vouches for 
the accuracy and completeness of the data.
Patients
Patients 18 years of age or older with symptoms of 
unstable angina lasting at least 10 minutes with-
in the preceding 24 hours were eligible for enroll-
ment if one or more of the following criteria were 
met: new ST-segment depression or transient ele-
vation of at least 1 mm; elevations in the tropo-
nin I, troponin T, or creatine kinase MB levels; 
known coronary artery disease; or all four other 
variables for predicting Thrombolysis in Myocar-
dial Infarction (TIMI) risk scores for unstable an-
gina.12 Exclusion criteria were myocardial infarc-
tion associated with acute ST-segment elevation or 
shock; bleeding diathesis or major bleeding epi-
sode within 2 weeks before the episode of angina; 
thrombocytopenia; a calculated creatinine clear-
ance rate of less than 30 ml per minute; recent ad-
ministration of abciximab, warfarin, fondapar i-
nux, fibrinolytic agents, bivalirudin, or two or more 
doses of low-molecular-weight heparin; and allergy 
to any of the study drugs or to iodinated contrast 
medium that could not be controlled in advance 
with medication. The study was approved by the 
institutional review board or ethics committee at 
each participating center, and all patients provid-
ed written, informed consent.
Randomization and study protocol
Telephone randomization was performed in blocks 
of six, stratified according to the site and the use 
of or intent to administer a thienopyridine before 
angiography. Patients were assigned equally in 
open-label fashion to one of the following three 
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antithrombotic regimens that were started im-
mediately after randomization: heparin plus a gly-
coprotein IIb/IIIa inhibitor (the control group), bi-
valirudin plus a glycoprotein IIb/IIIa inhibitor, or 
bivalirudin alone (Fig. 1). Either unfractionated 
heparin or enoxaparin was allowed in the control 
group. However, each site was required to prespec-
ify one agent and then use it exclusively, unless one 
of the types of heparin had been administered be-
fore randomization, in which case that same agent 
was continued in order to minimize crossovers.13
Detailed antithrombotic dosing recommenda-
tions for the trial have been described previously.11 
Unfractionated heparin was administered as an 
intravenous bolus of 60 IU per kilogram of body 
weight plus an infusion of 12 IU per kilogram per 
hour to achieve an activated partial-thromboplas-
tin time of 50 to 75 seconds before angiography 
and an activated clotting time of 200 to 250 sec-
onds during PCI. One milligram of enoxaparin per 
kilogram was administered subcutaneously twice 
a day before angiography. An intravenous bolus of 
an additional 0.3 mg per kilogram was adminis-
tered before PCI if the most recent subcutaneous 
dose had been given more than 8 hours earlier, or 
an intravenous bolus of an additional 0.75 mg per 
kilogram was administered before PCI if the most 
recent subcutaneous dose had been given more 
than 16 hours earlier. Bivalirudin was begun be-
fore angiography, with an intravenous bolus of 
0.1 mg per kilogram and an infusion of 0.25 mg 
per kilogram per hour.14,15 Before PCI, an addi-
tional intravenous bolus of 0.5 mg per kilogram 
was administered, and the infusion was increased 
to 1.75 mg per kilogram per hour.9 All antithrom-
botic agents were discontinued according to the 
protocol at the completion of angiography or PCI 
but could be continued at low doses at the discre-
tion of the operator. Antithrombotic monitoring 
was not performed in patients who were treated 
with enoxaparin or bivalirudin.
Patients assigned to heparin plus glycoprotein 
13,819 Patients with moderate- or high-risk acute coronary
syndromes randomly assigned to treatment
4604 Assigned to bivalirudin plus
a GP IIb/IIIa inhibitor
4603 Assigned to unfractionated
heparin or enoxaparin plus a GP
IIb/IIIa inhibitor
4580 Available for follow-up
at 30±5 days
4587 Available for follow-up
at 30±5 days
2294 Randomly
assigned to
initiation of GP
IIb/IIIa inhibitors
at randomization
2309 Randomly
assigned to 
deferred initiation
of GP IIb/IIIa
inhibitors in the
catheterization
laboratory for PCI
2293 Randomly
assigned to 
deferred initiation
of GP IIb/IIIa
inhibitors in the
catheterization
laboratory for PCI
16 Excluded
10 Lost to follow-up
6 Withdrew consent
24 Excluded
17 Lost to follow-up
7 Withdrew consent
30 Excluded
20 Lost to follow-up
10 Withdrew consent
4612 Assigned to bivalirudin alone
4582 Available for follow-up
at 30±5 days
2311 Randomly
assigned to
initiation of GP
IIb/IIIa inhibitors
at randomization
Figure 1. Enrollment, Randomization, and Follow-up of the Patients in the Trial.
GP denotes glycoprotein.
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IIb/IIIa inhibitors or bivalirudin plus glycoprotein 
IIb/IIIa inhibitors were randomly assigned again 
in a two-by-two factorial design to treatment with 
glycoprotein IIb/IIIa inhibitors, in all patients im-
mediately after randomization (the “upstream” 
group), or to deferred treatment with glycoprotein 
IIb/IIIa inhibitors, for use only in patients under-
going PCI starting in the cardiac catheterization 
laboratory (Fig. 1).16-19 The results of this subran-
domization are not reported here; the results are 
reported with the upstream and deferred sub-
groups pooled. The use of glycoprotein IIb/IIIa 
inhibitors was permitted before angiography in 
patients with severe breakthrough ischemia who 
were randomly assigned to deferred glycoprotein 
IIb/IIIa inhibitor use or bivalirudin monotherapy 
and was also permitted during PCI in patients re-
ceiving bivalirudin monotherapy who had proce-
dural complications.11
Angiography was performed in all patients 
within 72 hours after randomization. Patients were 
then triaged to PCI, CABG, or medical manage-
ment at the discretion of the physician. Aspirin, 
300 to 325 mg orally or 250 to 500 mg intrave-
nously, was administered daily during the initial 
hospitalization, followed by 75 to 325 mg daily 
indefinitely after discharge. The initial dose and 
timing of clopidogrel were left to the discretion of 
the investigator according to local standards, al-
though a loading dose of 300 mg or more was 
recommended in all patients no later than 2 hours 
after PCI. A daily dose of 75 mg of clopidogrel was 
recommended for 1 year in all patients with coro-
nary artery disease.
End Points
The following three primary 30-day end points, 
measured as cumulative events occurring within 
25 to 35 days after randomization, were prespec-
ified: a composite ischemia end point (death from 
any cause, myocardial infarction, or unplanned re-
vascularization for ischemia), major bleeding (not 
related to CABG), and a net clinical outcome end 
point (defined as the occurrence of the compos-
ite ischemia end point or major bleeding). Defini-
tions of the primary end points have been previ-
ously detailed.11 Major bleeding was defined as the 
cumulative occurrence within 25 to 35 days after 
randomization of intracranial or intraocular bleed-
ing, hemorrhage at the access site requiring inter-
vention, hematoma with a diameter of at least 5 cm, 
a reduction in hemoglobin levels of at least 4 g per 
deciliter without an overt bleeding source or at 
least 3 g per deciliter with such a source, reopera-
tion for bleeding, or transfusion of a blood prod-
uct. A clinical events committee that was unaware 
of the treatment assignments adjudicated all pri-
mary end-point events with the use of original 
source documents.
Statistical Analysis
The trial was powered for separate comparisons 
between the control group and each of the two in-
vestigational groups. We used sequential noninfe-
riority and superiority analyses with hierarchical 
end-point testing, with the type I error controlled 
by the Benjamini and Hochberg procedure,20 as 
previously described.11 Noninferiority was declared 
if the upper limit of the one-sided 97.5% confi-
dence interval (CI) for the event rate in the inves-
tigational group did not exceed a relative margin 
of 25% from the event rate in the control group, 
equivalent to a one-sided test with an alpha value 
of 0.025. A two-sided alpha value of 0.05 was used 
for superiority testing. 
The anticipated 30-day event rates for the com-
posite ischemia end point, major bleeding, and 
the net clinical outcome end point were 6.5%, 
9.0%, and 12.4%, respectively, in the control group; 
5.3%, 7.5%, and 10.3%, respectively, in the group 
receiving bivalirudin plus glycoprotein IIb/IIIa in-
hibitors; and 6.5%, 6.0%, and 10.5%, respectively, 
in the group receiving bivalirudin alone.11 For the 
comparison of bivalirudin plus glycoprotein IIb/IIIa 
inhibitors with heparin plus glycoprotein IIb/IIIa 
inhibitors, with 4600 patients in each group, the 
trial had more than 99% statistical power to dem-
onstrate noninferiority for the three primary end 
points and 88% power to demonstrate superiority 
for the net clinical outcome end point. For the 
comparison of bivalirudin alone with heparin plus 
glycoprotein IIb/IIIa inhibitors, the trial had 87% 
power to demonstrate noninferiority for the com-
posite ischemia end point, 99% power to demon-
strate both noninferiority and superiority for major 
bleeding, and 99% and 81% power to demonstrate 
noninferiority and superiority, respectively, for the 
net clinical outcome end point.
Categorical variables were compared with the 
chi-square test or Fisher’s exact test. Continuous 
variables were compared with the nonparametric 
Wilcoxon rank-sum test. Time-to-event distribu-
tions were displayed according to the Kaplan–Mei-
er method and were compared with the use of the 
The New England Journal of Medicine 
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log-rank test. All outcomes were evaluated by in-
tention-to-treat analyses.
R esult s
Patients
Between August 23, 2003, and December 5, 2005, 
we enrolled 13,819 patients with acute coronary 
syndromes at 450 centers in 17 countries. Baseline 
characteristics were well balanced among the study 
groups (Table 1). The median age of the patients 
was 63 years, and 70% were men. Myocardial in-
farction without ST-segment elevation (elevated 
baseline creatine kinase MB or troponin levels) was 
present in 59% of patients, whereas 41% had un-
stable angina.
Angiography was performed during the initial 
hospitalization in 99% of patients at a median of 
19.6 hours after admission, after which 56% of the 
patients underwent PCI, 11% underwent CABG, 
and 33% received medical therapy (Table 2). Stents 
were used in 93% of patients undergoing PCI, 65% 
Table 1. Baseline Characteristics of the Patients.
Characteristic
Unfractionated 
Heparin or Enoxaparin 
plus Glycoprotein 
IIb/IIIa Inhibitors
(N = 4603)
Bivalirudin plus 
Glycoprotein IIb/IIIa 
Inhibitors
(N = 4604)
Bivalirudin Alone
(N = 4612)
Age — yr
Median 63 63 63
Range 23–91 21–95 20–92
Weight — kg
Median 83 83 84
Interquartile range 73–95 73–95 73–96
Male sex — no. (%) 3249 (70.6) 3218 (69.9) 3195 (69.3)
Medical history — no./total no. (%)
Diabetes 1298/4564 (28.4) 1267/4568 (27.7) 1287/4577 (28.1)
Insulin-requiring diabetes 389/4564 (8.5) 396/4568 (8.7) 408/4577 (8.9)
Hypertension 3058/4577 (66.8) 3074/4577 (67.2) 3080/4593 (67.1)
Hyperlipidemia 2580/4511 (57.2) 2588/4508 (57.4) 2579/4521 (57.0)
Current smoker 1308/4508 (29.0) 1323/4522 (29.3) 1312/4527 (29.0)
Myocardial infarction 1419/4493 (31.6) 1372/4491 (30.5) 1431/4499 (31.8)
Percutaneous coronary intervention 1780/4567 (39.0) 1720/4554 (37.8) 1820/4562 (39.9)
Coronary-artery bypass grafting 834/4588 (18.2) 801/4592 (17.4) 830/4594 (18.1)
Renal insufficiency* 826/4298 (19.2) 824/4303 (19.1) 818/4339 (18.9)
Elevation of cardiac biomarker levels — 
no./total no. (%)
2503/4213 (59.4) 2479/4238 (58.5) 2570/4263 (60.3)
Elevation of troponin levels — no./total no. (%) 2290/3931 (58.3) 2276/3982 (57.2) 2349/3971 (59.2)
ST-segment deviation ≥1 mm — no./total no. (%) 1618/4598 (35.2) 1628/4599 (35.4) 1579/4607 (34.3)
Elevation of cardiac biomarker levels or ST-seg-
ment deviation ≥1 mm — no./total no. (%)
3171/4340 (73.1) 3119/4362 (71.5) 3173/4385 (72.4)
TIMI risk score — no./total no. (%)†
0–2 654/4070 (16.1) 630/4090 (15.4) 637/4077 (15.6)
3–4 2184/4070 (53.7) 2269/4090 (55.5) 2223/4077 (54.5)
5–7 1232/4070 (30.3) 1191/4090 (29.1) 1217/4077 (29.9)
* Renal insufficiency was defined as a calculated creatinine clearance rate of less than 60 ml per minute as determined 
by the Cockcroft–Gault equation.
† Thrombolysis in Myocardial Infarction (TIMI) risk scores assess the prognosis for patients with acute coronary syn-
dromes; higher scores indicate greater risk.12
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of whom received drug-eluting stents. In the con-
trol group, after randomization, unfractionated 
heparin and enoxaparin were selected with simi-
lar frequencies. The median maximum activated 
clotting time among patients undergoing PCI with 
unfractionated heparin was 239 seconds (inter-
quartile range, 211 to 291).
Glycoprotein IIb/IIIa inhibitors were used dur-
ing PCI in 9.1% of patients treated with bivaliru-
din alone (for procedural complications in 6.5%). 
The most common procedural complications lead-
ing to the use of glycoprotein IIb/IIIa inhibitors 
were the presence of new or suspected thrombus, 
slow flow (TIMI flow grade 2), or no reflow (TIMI 
flow grade 0 or 1).
In-hospital adverse events
On the basis of on-site reporting without central 
adjudication, the most frequent nonprocedural ad-
verse events during the initial hospitalization were 
chest pain (3.6% of patients), headache (3.1%), back 
pain (2.8%), and nausea (2.3%), which occurred 
with similar frequency in the three trial groups. 
Procedural complications were reported more fre-
quently in the group assigned to bivalirudin alone 
than in the other two groups, a finding that was 
consistent with the protocol-specified requirement 
to provide an indication for provisional use of gly-
coprotein IIb/IIIa inhibitors. Blinded angiographic 
analyses performed at a core laboratory showed no 
significant differences in the incidence, nature, or 
Table 2. Procedures and Study Medications.
Variable
Unfractionated 
Heparin or 
Enoxaparin plus 
Glycoprotein IIb/IIIa 
Inhibitors
(N = 4603)
Bivalirudin plus 
Glycoprotein IIb/IIIa 
Inhibitors
(N = 4604)
Bivalirudin Alone
(N = 4612)
Angiography performed — no. (%) 4565 (99.2) 4547 (98.8) 4561 (98.9)
Hours from admission to angiography — median (interquartile range)* 19.7 (7.0–29.3) 19.5 (7.0–28.2) 19.8 (7.3–29.0)
Hours from admission to randomization — median (interquartile range) 6.1 (2.0–15.5) 6.0 (2.0–15.4) 6.0 (2.0–15.1)
Hours from randomization to initiation of antithrombotic study drug 
— median (interquartile range)†
0.4 (0.1–0.9) 0.7 (0.4–1.1) 0.6 (0.3–1.0)
Hours from antithrombotic study drug to angiography — median 
(interquartile range)†
4.0 (1.2–18.1) 3.5 (0.9–18.2) 3.9 (1.0–19.0)
Hours from antithrombotic study drug to PCI — median (interquartile 
range)†
4.1 (1.5–19.0) 3.9 (1.3–19.0) 4.1 (1.4–20.0)
Treatment strategy — no. (%)
PCI 2561 (55.6) 2609 (56.7) 2619 (56.8)
Coronary-artery bypass grafting 549 (11.9) 499 (10.8) 491 (10.6)
Medical management 1493 (32.4) 1496 (32.5) 1502 (32.6)
Antithrombotic medications — no. (%)
Before randomization 3010 (65.4) 2907 (63.1) 2945 (63.9)
Unfractionated heparin 1910 (41.5) 1858 (40.4) 1870 (40.5)
Low-molecular-weight heparin 1209 (26.3) 1144 (24.8) 1172 (25.4)
After randomization and before angiography
Unfractionated heparin 2206 (47.9) 82 (1.8) 66 (1.4)
Enoxaparin 2182 (47.4) 17 (0.4) 20 (0.4)
Bivalirudin 6 (0.1) 4420 (96.0) 4471 (96.9)
Antiplatelet medications
Aspirin before angiography or PCI — no./total no. (%) 4446/4535 (98.0) 4427/4528 (97.8) 4441/4535 (97.9)
Thienopyridine before angiography or PCI — no./total no. (%) 2842/4526 (62.8) 2924/4520 (64.7) 2911/4531 (64.2)
Clopidogrel 2819/4527 (62.3) 2904/4520 (64.2) 2897/4531 (63.9)
Ticlopidine   42/4534 (0.9)   36/4524 (0.8)   31/4531 (0.7)
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angiographic outcome of procedural complications 
among the three groups.
Clinical outcomes
Bivalirudin plus glycoprotein IIb/IIIa inhibitors, as 
compared with heparin plus glycoprotein IIb/IIIa 
inhibitors, resulted in noninferior 30-day rates of 
the composite ischemia end point (7.7% and 7.3%, 
respectively; P = 0.39; relative risk, 1.07; 95% CI, 
0.92 to 1.23), major bleeding (5.3% and 5.7%; 
P = 0.38; relative risk, 0.93; 95% CI, 0.78 to 1.10), 
and the net clinical outcome end point (11.8% and 
11.7%; P = 0.93; relative risk, 1.01; 95% CI, 0.90 to 
1.12). Bivalirudin alone, as compared with heparin 
plus glycoprotein IIb/IIIa inhibitors, resulted in a 
noninferior rate of the composite ischemia end 
point (7.8% and 7.3%, respectively; P = 0.32; relative 
risk, 1.08; 95% CI, 0.93 to 1.24), a significantly 
reduced rate of major bleeding (3.0% and 5.7%; 
P<0.001; relative risk, 0.53; 95% CI, 0.43 to 0.65), 
and a reduced rate of the net clinical outcome end 
point (10.1% and 11.7%; P = 0.02; relative risk, 0.86; 
95% CI, 0.77 to 0.97) (Table 3 and Fig. 2). Bivaliru-
din monotherapy also decreased the rates of bleed-
ing from any cause (including bleeding related to 
CABG), minor bleeding, major and minor bleeding 
according to the TIMI scale, and blood transfusion 
(Table 3).
The treatment effects of bivalirudin monother-
apy were consistent among multiple prespecified 
subgroups, including patients who had positive 
tests for biomarkers, those undergoing PCI, those 
who were randomly assigned to immediate or 
deferred treatment with glycoprotein IIb/IIIa in-
Table 2. (Continued.)
Variable
Unfractionated 
Heparin or 
Enoxaparin plus 
Glycoprotein IIb/IIIa 
Inhibitors
(N = 4603)
Bivalirudin plus 
Glycoprotein IIb/IIIa 
Inhibitors
(N = 4604)
Bivalirudin Alone
(N = 4612)
Glycoprotein IIb/IIIa inhibitor before randomization — no. (%) 374 (8.1) 350 (7.6) 307 (6.7)
Eptifibatide 222 (4.8) 213 (4.6) 193 (4.2)
Tirofiban 154 (3.3) 136 (3.0) 114 (2.5)
Abciximab 13 (0.3) 10 (0.2) 9 (0.2)
Glycoprotein IIb/IIIa inhibitor after randomization and before angio-
graphy — no. (%)‡
2305 (50.1) 2248 (48.8) 31 (0.7)
Eptifibatide 1486 (32.3) 1448 (31.5) 19 (0.4)
Tirofiban 802 (17.4) 784 (17.0) 11 (0.2)
Abciximab 17 (0.4) 16 (0.3) 1 (<0.1)
Glycoprotein IIb/IIIa inhibitor during PCI — no./total no. (%) 2473/2561 (96.6) 2523/2609 (96.7) 238/2619 (9.1)
Eptifibatide 1526/2561 (59.6) 1588/2609 (60.9) 119/2619 (4.5)
Tirofiban  492/2561 (19.2)  513/2609 (19.7)  20/2619 (0.8)
Abciximab  455/2561 (17.8)  425/2609 (16.3)  99/2619 (3.8)
Medications taken regularly after hospital discharge through 30 days — 
no./total no. (%)
Aspirin 4088/4411 (92.7) 4076/4388 (92.9) 4094/4394 (93.2)
Thienopyridine 2940/4411 (66.7) 3012/4388 (68.6) 3013/4394 (68.6)
Beta-blocker 3363/4411 (76.2) 3387/4388 (77.2) 3361/4394 (76.5)
Angiotensin converting–enzyme inhibitor or angiotensin-receptor 
blocker
2589/4411 (58.7) 2619/4388 (59.7) 2642/4394 (60.1)
Statin 3530/4411 (80.0) 3510/4388 (80.0) 3549/4394 (80.8)
* Data are not normally distributed, so median durations of the subgroups of hours from admission to angiography do not add up to the me-
dian duration of the total hours from admission to angiography.
† This category includes patients who were not receiving an antithrombotic agent before randomization.
‡ This category includes patients in whom the glycoprotein IIb/IIIa inhibitor was administered before randomization.
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Figure 2. Kaplan–Meier Time-to-Event Curves for the End Points of Net Clinical Outcome (Panel A), Composite 
Ischemia (Panel B), and Major Bleeding (Panel C).
The primary end points were measured at 30±5 days; thus, follow-up is reported to 35 days. The event rate for each 
curve refers to the cumulative rate at 35 days. P values are for comparisons with the control group (unfractionated hepa-
rin or enoxaparin plus glycoprotein IIb/IIIa inhibitors). GP denotes glycoprotein. The thick solid line represents heparin 
plus GP IIb/IIIa inhibitor; the dotted line, bivalirudin plus GP IIb/IIIa inhibitor; and the thin solid line, bivalirudin alone.
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hibitors, and those who did not undergo early 
angiography (Fig. 3; see also the figure in the Sup-
ple mentary Appendix). Among the 2472 patients 
who underwent angiography or intervention more 
than 24 hours after randomization (median, 45.0 
hours; interquartile range, 28.4 to 69.2), bivaliru-
din monotherapy, as compared with heparin plus 
glycoprotein IIb/IIIa inhibitors, resulted in a simi-
lar rate of the composite ischemia end point (8.9% 
and 9.1%, P = 0.89), a reduced rate of major bleed-
ing (3.3% and 8.9%, P<0.001), and a reduced rate 
of the net clinical outcome end point (11.4% and 
16.4%, P = 0.003).
An interaction effect with borderline signifi-
cance (P = 0.054) was noted in only one subgroup 
analysis. Among patients receiving a thienopyri-
dine before angiography or PCI, ischemic events 
occurred with similar frequency in the bivalirudin 
monotherapy group and in the group assigned to 
heparin plus a glycoprotein IIb/IIIa inhibitor (7.0% 
and 7.3%, respectively; relative risk, 0.97; 95% CI, 
0.80 to 1.17). In contrast, among patients who did 
not receive a thienopyridine before angiography 
or PCI, ischemic events were more frequent with 
bivalirudin monotherapy than with heparin plus a 
glycoprotein IIb/IIIa inhibitor (9.1% and 7.1%; 
relative risk, 1.29; 95% CI, 1.03 to 1.63). Bivaliru-
din monotherapy, as compared with heparin plus 
a glycoprotein IIb/IIIa inhibitor, reduced major 
bleeding regardless of whether patients were pre-
treated with a thienopyridine (Fig. 3).
Patients in the control group who received 
A Composite Ischemia
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Figure 3. Selected Subgroup Analyses for the 30-Day Rates of Composite Ischemia (Panel A) and Major Bleeding (Panel B, facing page).
Patients randomly assigned to heparin plus glycoprotein IIb/IIIa inhibitors were compared with those assigned to bivalirudin alone. The 
black boxes represent the relative risk with 95% CIs (horizontal lines). P values are for the interaction between the variable and the rela-
tive treatment effect. GP denotes glycoprotein, CK MB creatine kinase MB, troponin troponin I or T, PCI percutaneous coronary inter-
vention, CABG coronary-artery bypass grafting, and NA not applicable (since the patients in the group receiving bivalirudin alone did 
not receive routine upstream or deferred glycoprotein IIb/IIIa inhibitors).
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unfractionated heparin and those who received 
enoxaparin had similar 30-day rates of the com-
posite ischemia end point (6.8% and 7.7%, respec-
tively; P = 0.29), major bleeding (5.9% and 5.5%, 
P = 0.55), and the net clinical outcome end point 
(11.5% and 11.8%, P = 0.75). Baseline renal insuf-
ficiency was associated with an increased rate of 
hemorrhagic complications with all antithrom-
botic agents. However, the relative increase in the 
rate of major bleeding associated with a baseline 
calculated creatinine clearance of less than 60 ml 
per minute, as compared with 60 ml per minute or 
more, was similar among patients receiving enoxa-
parin, those receiving unfractionated heparin, and 
those receiving bivalirudin monotherapy (9.5% and 
4.4%, 10.1% and 4.9%, and 6.2% and 2.4%, respec-
tively).
Discussion
In this large-scale, prospective, randomized trial 
involving patients with moderate- or high-risk 
acute coronary syndromes who were undergoing 
early invasive management, the use of bivalirudin 
plus a glycoprotein IIb/IIIa inhibitor was associ-
ated with rates of ischemic and hemorrhagic com-
plications that were noninferior to those associ-
ated with the use of heparin (either unfractionated 
heparin or enoxaparin) plus a glycoprotein IIb/IIIa 
inhibitor. In contrast, bivalirudin monotherapy, 
with provisional use of glycoprotein IIb/IIIa inhibi-
tors in less than 10% of patients, was associated 
with rates of ischemic events that were noninferior 
to those associated with heparin plus glycoprotein 
IIb/IIIa inhibition but was associated with a sig-
nificantly reduced incidence of major bleeding.
Formal subgroup analysis revealed no signifi-
cant interactions between the primary study end 
points and numerous important demographic and 
treatment variables, with the possible exception 
of the administration of a thienopyridine before 
angiography or PCI. Although the time from ad-
ministration of the study drug to angiography 
was relatively short (reflecting the growing rec-
B Major Bleeding 
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ognition that clinical outcomes are optimized 
with rapid catheterization in acute coronary syn-
dromes),21 bivalirudin monotherapy was also as-
sociated with a significantly lower risk of bleed-
ing and similar rates of ischemia in the subgroup 
of patients for whom the interval from random-
ization to angio graphy or intervention was more 
than 24 hours.
In approximately 64% of patients, a thienopyri-
dine (clopidogrel in most instances) was already 
in use or was administered before angiography or 
PCI. In such patients, the point estimate for com-
posite ischemic events was similar with bivali-
rudin monotherapy and with heparin plus glyco-
protein IIb/IIIa inhibitors. In contrast, the point 
estimate for adverse ischemic events was slightly 
greater with bivalirudin monotherapy than with 
heparin plus glycoprotein IIb/IIIa inhibitors in pa-
tients who were not pretreated with a thienopyri-
dine. Information about the exact timing of pre-
treatment with clopidogrel was not available for 
all patients, and platelet responsiveness testing was 
not performed, precluding an in-depth examina-
tion of the relationship between inhibition of the 
P2Y12 platelet receptor and the efficacy of bivali-
rudin. Moreover, given the borderline statistical 
significance of the interaction (P = 0.054) and the 
risk of a spurious finding from examination of 
multiple subgroups, caution against overinterpre-
tation is warranted.22 Nonetheless, the administra-
tion of a thienopyridine before angiography may 
be desirable to optimize outcomes with a regimen 
of bivalirudin monotherapy, an approach that is 
consistent with experimental observations.23,24
Several limitations of the present study deserve 
comment. First, the logistic complexities of the 
trial necessitated an open-label design, which in-
troduced the potential for bias. However, the fre-
quency of the provisional use of glycoprotein IIb/
IIIa inhibitors for procedural complications related 
to PCI among patients in the group receiving bi-
valirudin monotherapy was nearly identical to that 
in the double-blind REPLACE-2 trial,9 and all end-
point events were adjudicated by an independent 
committee that was unaware of the treatment as-
signments.
Second, 59% of the study cohort presented with 
myocardial infarction without ST-segment eleva-
tion, a percentage lower than that in the Superior 
Yield of the New Strategy of Enoxaparin, Revas-
cularization and Glycoprotein IIb/IIIa Inhibitors 
(SYNERGY) trial (which specifically recruited only 
high-risk patients),13 though similar to the per-
centage in other recent large-scale trials of acute 
coronary syndromes.25,26 Nevertheless, adverse 
composite ischemic events occurred with nearly 
identical frequency in patients in the control and 
bivalirudin-monotherapy groups, even among the 
highest-risk patients enrolled (i.e., 2449 patients 
with a TIMI risk score of 5 to 7). Bivalirudin mono-
therapy was also particularly effective in the sub-
group of patients with baseline TIMI risk scores 
of 0 to 2. However, enrollment criteria were such 
that 80.1% of this subgroup met the classic high-
risk criteria for either positive biomarkers or ST-
segment deviation at baseline. The results of the 
present study do not apply, however, to patients 
with acute coronary syndromes that are managed 
either solely with a noninvasive strategy, without 
diagnostic angiography and intended revascular-
ization, or for a prolonged period (>72 hours) be-
fore catheterization. Further study is also required 
to determine the optimal pharmacologic regimen 
for patients with severe renal insufficiency (creati-
nine clearance, <30 ml per minute), who were ex-
cluded from enrollment.
Third, as in other recent acute coronary syn-
drome trials,13 a significant proportion of patients 
were pretreated with either unfractionated or low-
molecular-weight heparin before randomization. 
Protocol procedures limited the rate of intragroup 
crossovers from treatment before to treatment af-
ter randomization to less than 6% in the control 
group, whereas more than 60% of patients as-
signed to bivalirudin were exposed to heparin be-
fore randomization. Nonetheless, the effects of 
bivalirudin monotherapy as compared with hepa-
rin plus a glycoprotein IIb/IIIa inhibitor were con-
sistent, regardless of whether an antithrombotic 
crossover occurred, as demonstrated in subgroup 
analyses.
Fourth, the 25% noninferiority margin that we 
used may be considered wide. Because the ob-
served rate of ischemic events in the control group 
was 7.3 percent, an estimated ischemic-event rate 
as high as 9.1% in the test groups would have been 
considered noninferior, even though it might be 
regarded as clinically important. However, given 
the observed event rates and confidence intervals, 
there was a 95.0% likelihood that the incidence 
of composite ischemia in the bivalirudin-mono-
therapy group is less than 20% higher than the 
incidence in the control group.
In summary, we found that in patients with 
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unstable angina or myocardial infarction without 
ST-segment elevation who were undergoing early 
invasive management, the rates of ischemic events 
and bleeding were similar with the use of either 
bivalirudin or heparin when combined with the 
planned use of a glycoprotein IIb/IIIa inhibitor. 
When bivalirudin was used without a glycoprotein 
IIb/IIIa inhibitor, the frequency of ischemic events 
was similar to that with heparin plus a glycopro-
tein IIb/IIIa inhibitor, but the frequency of major 
bleeding was significantly reduced.
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